Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Large Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Record quarter with strong organic growth in Labtech
AddLife's Interim Report for Q1 2021 is now available online at the company website. The Interim Report can be downloaded in pdf version.
Visit reports-en.add.life/delarsrapport-q1-2021
1 JANUARY - 31 MARCH 2021 (3 MONTHS)
- Net sales increased by 65 percent to SEK 1,736 million (1,053), of which organic growth amounted to 54 percent and acquired growth amounted to 17 percent.
- EBITA increased by 209 percent to SEK 326 million (106), corresponding to an EBITA-margin of 18.8 percent (10.0).
- Profit after tax increased by 318 percent to SEK 226 million (54).
- Earnings per share amounted to SEK 2.01 (0.48). Earnings per share for the last 12 months amounted to 6.16 SEK (4.63).
- Cash flow from operating activities amounted to SEK 184 million (80).
- The equity ratio was 48 percent (46).
- Return on working capital (P/WC) amounted to 122 percent (103).
- Two acquisitions were completed after the end of the reporting period, Vision Ophthalmology Group and Helathcare 21. The acquisitions are expected to add annual net sales of SEK 2,400 million and EBITA of approximately SEK 310 million. The acquisitions have been financed through new credits of SEK 2,250 million and new share issue of 7,951,958 Class B-shares.
Stockholm, 28 April 2021 AddLife AB (publ)
For more information, contact;
Kristina Willgård, CEO, kristina.willgard@add.life,+46 70 510 12 23
Martin Almgren, CFO, martin.almgren@add.life,+46 70 228 15 45
www.add.life
Teleconference
Investors. analysts and the media are invited to a teleconference at which CEO Kristina Willgård and CFO Martin Almgren will present the interim report. The presentation will be given in English and take about 20 minutes. after which there will be an opportunity to ask questions. It will be recorded and made available online. If this is your first time using Teams, you will be asked to download an app.
The teleconference will be at 10 a.m. on 28 April 2021
If you wish to participate via teleconference, please follow this link>> (https://teams.microsoft.com/l/meetup-join/19%3ameeting_ZmRiNGUxNjAtODJjOS00NTNhLTk1YzUtZDQ2MzdiYzRlZTk3%40thread.v2/0?context=%7b%22Tid%22%3a%2220971130-9feb-4ac0-96f1-e7fbd0d840e4%22%2c%22Oid%22%3a%22f0c4cdd5-3797-4b6d-947a-2bfc2b19c038%22%7d)
Or call in (only sound) +46 8 505 376 58 Conferens-ID: 321 695 644#
The presentation is also available on AddLife YouTube >> (https://www.youtube.com/channel/UC_YiKbKavYICoTU37Y0C8pg)
AddLife is an European, independent player in the Life Science industry that offers high-quality products, services and advice to both the private and public sectors. AddLife has about 1,800 employees in some 70 operating subsidiaries. The Group currently has net sales of around SEK 7 billion. AddLife shares are listed on Nasdaq Stockholm.
This information is information that AddLife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 28 April 2021 at 07:45 a.m. CET.